Scarica l'app Stockscreener
0.1595
5.00%
-0.0065
Precedente Chiudi:
$0.166
Aprire:
$0.1672
Volume 24 ore:
505.83K
Relative Volume:
0.48
Capitalizzazione di mercato:
$12.82M
Reddito:
$1.16M
Utile/perdita netta:
$-39.74M
Rapporto P/E:
-0.2573
EPS:
-0.62
Flusso di cassa netto:
$-35.02M
1 W Prestazione:
-18.63%
1M Prestazione:
-37.64%
6M Prestazione:
-33.96%
1 anno Prestazione:
-41.70%
Intervallo 1D:
$0.153
$0.17
Intervallo di 1 settimana:
$0.1515
$0.184
Portata 52W:
$0.1406
$0.63
Glycomimetics Inc Stock (GLYC) Company Profile
Nome
Glycomimetics Inc
Settore
Industria
Telefono
240-243-1201
Indirizzo
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Confronta GLYC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.1572 | 12.82M | 1.16M | -39.74M | -35.02M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.16 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
519.75 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
305.04 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
581.74 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
271.99 | 27.80B | 3.81B | -644.79M | -669.77M | -6.24 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-26 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-22 | Iniziato | CapitalOne | Overweight |
| 2021-11-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-11-14 | Iniziato | ROTH Capital | Buy |
| 2019-08-05 | Downgrade | Jefferies | Buy → Hold |
| 2019-08-05 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | Downgrade | SunTrust | Buy → Hold |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2018-12-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-07-26 | Iniziato | SunTrust | Buy |
| 2015-03-17 | Reiterato | Stifel | Buy |
Mostra tutto
Glycomimetics Inc Borsa (GLYC) Ultime notizie
Cantor Fitzgerald Comments on GlycoMimetics FY2026 Earnings - Defense World
GlycoMimetics (NASDAQ:GLYC) Shares to Reverse Split on Monday, June 16th - Defense World
Where Do Analysts Think The GlycoMimetics Inc (NASDAQ: GLYC) Is Going - Stocksregister
Wellington Management Group LLP Takes Position in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
GlycoMimetics Stockholders Approve Merger with Crescent Biopharma - TipRanks
GlycoMimetics Stockholders Approve Proposed Merger With Crescent Biopharma And All Related Proposals - marketscreener.com
GlycoMimetics Stockholders Approve Merger with Crescent Biopharma and All Related Proposals - citybiz
GlycoMimetics (GLYC) Stockholders Approve Merger with Crescent Biopharma | GLYC Stock News - GuruFocus
GlycoMimetics announces 1-for-100 reverse stock split - Investing.com Australia
GlycoMimetics announces 1-for-100 reverse stock split By Investing.com - Investing.com Canada
GlycoMimetics stockholders approve proposed Crescent Biopharma merger - TipRanks
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals - Business Wire
GlycoMimetics Announces Merger Amidst Uncertainties - TipRanks
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference - The Manila Times
GlycoMimetics executives to depart amid merger plans - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, LRFC, RDW, GLYC on Behalf of Shareholders - TradingView
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NDOI, SSBK, BRDG on Behalf of Shareholders - GlobeNewswire Inc.
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
GlycoMimetics (NASDAQ:GLYC) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - marketscreener.com
GlycoMimetics: Q1 Earnings Snapshot - CT Insider
GLYCOMIMETICS INC SEC 10-Q Report - TradingView
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. to Host Earnings Call - ACCESS Newswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerGLYC, BRZH, PRA, FVNNU - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – GLYC, BRZH, PRA, FVNNU - TradingView
GLYCGlycomimetics Latest Stock News & Market Updates - Stock Titan
A Stock Analysis Of GlycoMimetics Inc’s (GLYC) - Stocksregister
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Ratios Revealed: Decoding GlycoMimetics Inc (GLYC)’s Financial Health - DWinneX
GlycoMimetics Inc (GLYC Stock: A Sea of Opportunity - investchronicle.com
Cantor Fitzgerald initates GlycoMimetics Inc (GLYC) rating to an Overweight - knoxdaily.com
GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com
GlycoMimetics, Inc. (GLYC) Stock Report: Analyst Ratings Signal Potential in Biotech Space - DirectorsTalk Interviews
Press Release Distribution & PR Platform - ACCESS Newswire
A Look at GlycoMimetics Inc (GLYC) Shares in the Recent Past Indicates Growth - Sete News
GLYC Shares Experience Surge in Value - knoxdaily.com
GlycoMimetics (NASDAQ:GLYC) Stock Price Passes Below 200 Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc (GLYC) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Understanding GLYC stock ratios for better investment decisions - uspostnews.com
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
Wellington Management Group LLP Makes New Investment in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
Glycomimetics Inc Azioni (GLYC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Glycomimetics Inc Azioni (GLYC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 10% Owner |
Aug 07 '24 |
Sale |
0.18 |
61,488 |
11,197 |
6,578,438 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 05 '24 |
Sale |
0.19 |
164,523 |
30,996 |
6,695,658 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 06 '24 |
Sale |
0.18 |
55,732 |
10,188 |
6,639,926 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 02 '24 |
Sale |
0.20 |
286,200 |
57,354 |
6,860,181 |
| Invus Public Equities, L.P. | 10% Owner |
Aug 01 '24 |
Sale |
0.22 |
63,564 |
13,743 |
7,146,381 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 30 '24 |
Sale |
0.22 |
756,835 |
167,185 |
7,209,945 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 29 '24 |
Sale |
0.24 |
363,949 |
85,637 |
7,966,780 |
| Invus Public Equities, L.P. | 10% Owner |
Jul 26 '24 |
Sale |
0.24 |
258,335 |
62,440 |
8,330,729 |
| Rock Edwin | Chief Medical Officer |
Jun 20 '24 |
Buy |
0.25 |
190,000 |
48,108 |
565,403 |
| Rock Edwin | Chief Medical Officer |
Jun 21 '24 |
Buy |
0.27 |
115,000 |
30,716 |
680,403 |
0.06%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):